Bone Biologics Corp
BBLG· Nasdaq
Who holds Bone Biologics Corp, from the managers’ Form 13F reports for the quarter ended Sep 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 290K | New | $143.9K | 0.1% | Nov 16, 2026 |
| Citadel Advisors LLC | 60K | +19.4% | $88.9K | 0% | Nov 16, 2026 |
| Susquehanna International Group, LLP | 12K | New | $5.9K | 0% | Nov 16, 2026 |
| UBS Group AG | 898 | +75.0% | $3.4K | 0% | Nov 10, 2026 |
| Tower Research Capital LLC (TRC) | 2.2K | +14.9% | $1.1K | 0% | Nov 16, 2026 |
| SBI Securities Co., Ltd. | 341 | +48.3% | $169 | 0% | Oct 22, 2026 |
| HRT Financial LP | 68K | New | $33 | 0.1% | Nov 13, 2026 |
| Virtu Financial LLC | 20.7K | New | $10 | 0.1% | Nov 17, 2026 |
| Caitong International Asset Management Co., Ltd | 1 | New | $0 | 0% | Oct 29, 2026 |